Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

China Health care / Quantitative Analysis

<ul>
<li>Hangzhou Bioer is a leading PCR player in China. The company is looking to raise up to USD 200m via a Hong Kong listing.</li>
<li>We look at the company's key segments and products. We think the company will face significant risk post-pandemic.</li>
<li>Its management and investor lineup are also not impressive. It also has risk of being sanctioned.</li>
</ul>


Hangzhou Bioer is a leading PCR player in China. The company is looking to raise up to USD 200m via a Hong Kong listing.
We look at the company's key segments and products. We think the company will face significant risk post-pandemic.
Its management and investor lineup are also not impressive. It also has risk of being sanctioned.


Hangzhou Bioer (杭州博日科技) Pre-IPO: COVID-19 Tailwind to Stop